Document is current
Any future updates will be listed below
-
Authors
van der Koog, Luke
Woest, Manon E.
Gorter, Iris C.
Verschut, Vicky
Elferink, Robin A. B.
Zuidhof, Annet B.
Nugraha, Dyan F.
Koloko Ngassie, Maunick L.
Bos, Sophie I. T.
Dhakad, Deepesh
Wolters, Justina C.
Horvatovich, Peter L.
Prakash, Y. S.
Timens, Wim
Yildirim, Önder A.
Brandsma, Corry-Anke
Frijlink, Henderik W.
Nagelkerke, Anika
Gosens, Reinoud
-
Funding
Funding for this research was provided by:
Stichting Astma Bestrijding (SAB 2021-021, SAB 2021-021, SAB 2021-021)
Rijksuniversiteit Groningen
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (184.034.019)
- License Information
-
More Information
Article History
Received: 2 December 2024
Accepted: 14 March 2025
First Online: 25 March 2025
Competing interests
: A patent has been filed on the therapeutic application of OGN (Patent title: Osteoglycin as regenerative agent in epithelial cells and tissues, Patent number: EP23179039.5). L.K., H.W.F., A.N., and R.G. hold the patent. In addition, L.K., H.W.F., A.N., and R.G. are co-founders and shareholders of the University of Groningen spin-off MimeCure BV.
